Does Amerigroup Cover Viagra? What Women Need to Know About Sexual Health Coverage

Why Women Ask About Viagra Coverage

The question makes sense. Sildenafil is one of the most recognized sexual health drugs in the world, and many women with low desire, difficulty with arousal, or pain-related sexual dysfunction wonder whether the drug that works for men might also work for them, and whether their insurance would pay for it. The short answer is that Amerigroup almost certainly will not cover Viagra for you as a woman, and the reason goes beyond a formulary decision. It starts with the science.

Sildenafil works by inhibiting phosphodiesterase type 5 (PDE5), which increases blood flow. In men with erectile dysfunction, that mechanism addresses the primary physiological problem. Female sexual dysfunction is far more heterogeneous. Low desire, arousal difficulties, orgasm disorders, and genitopelvic pain each have distinct underlying causes, and blood flow is only one piece of a much more complicated picture.

A 2003 Cochrane review of sildenafil in women found no consistent benefit for women with sexual arousal disorder, and subsequent trials did not change that conclusion enough for the FDA to grant approval. Because there is no FDA-approved indication for sildenafil in women's sexual dysfunction, insurance carriers including Amerigroup have no regulatory basis to classify it as a medically necessary treatment for female patients.

Sildenafil is sometimes prescribed off-label for specific conditions in women, including pulmonary arterial hypertension and, in some reproductive medicine contexts, uterine lining support during IVF cycles. Coverage in those cases depends entirely on the documented diagnosis code submitted by your prescriber, not the drug name.

How Amerigroup Plans Work and Why Coverage Varies

Amerigroup is a managed care organization operating under the Anthem/Elevance Health umbrella. It primarily serves Medicaid enrollees across roughly 20 states, and also offers Medicare Advantage and some ACA Marketplace products in select markets. Because Medicaid is jointly funded and state-administered, what Amerigroup covers in Georgia is not what it covers in Texas or Nevada.

Medicaid Managed Care Plans

Amerigroup Medicaid plans must cover all federally mandated Medicaid benefits, but sexual health drugs beyond contraception are not a federal mandate. States have wide discretion. Some states require their Medicaid managed care organizations to cover FDA-approved treatments for sexual dysfunction with prior authorization; others exclude them entirely. The Kaiser Family Foundation Medicaid benefits database documents these state-by-state variations, though it is not on our allow-list, so you should verify directly with your state Medicaid agency or call the Amerigroup member line at the number on the back of your card.

Medicare Advantage Plans

Medicare Part D generally excludes drugs used for sexual dysfunction from coverage, a statutory exclusion that dates to the Medicare Modernization Act. CMS has explicitly listed sexual dysfunction drugs as a coverage exclusion under Part D, which means an Amerigroup Medicare Advantage plan will not cover Viagra, flibanserin, or bremelanotide under the pharmacy benefit in most circumstances. There are narrow exceptions when the drug is prescribed for a non-excluded indication, such as pulmonary hypertension.

Marketplace and Commercial Plans

Amerigroup Marketplace plans follow ACA essential health benefit rules. Sexual health services as a category are not a named essential health benefit, so coverage again depends on state mandates and the specific plan design.

What Amerigroup Actually Does Cover for Women's Sexual Health

This is where the conversation gets more useful for you as a patient.

Preventive Sexual Health Services

Under the ACA, all Amerigroup non-grandfathered plans must cover certain preventive services at no cost to you. These include USPSTF-recommended STI screening and counseling, FDA-approved contraceptive methods, cervical cancer screening, and HPV vaccination. These are covered regardless of whether you are on a Medicaid, Medicare Advantage, or Marketplace plan.

Flibanserin (Addyi) for HSDD

Flibanserin is the only FDA-approved oral treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally, modulating serotonin, dopamine, and norepinephrine receptors rather than acting on blood flow. The approval was based on three Phase 3 trials (the BEGONIA, SNOWDROP, and VIOLET trials) showing a modest but statistically significant increase in satisfying sexual events and desire scores compared to placebo.

Whether Amerigroup covers flibanserin depends on your specific plan and state. Some Medicaid programs have added it to their formularies with prior authorization requirements; others have not. If your plan does cover it, expect to document that you have tried psychological counseling or therapy first, that your low desire is causing personal distress, and that you are not currently taking moderate or strong CYP3A4 inhibitors, which dangerously increase flibanserin exposure.

Bremelanotide (Vyleesi) for HSDD

Bremelanotide is FDA-approved as a subcutaneous self-injection for HSDD in premenopausal women. You inject it at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than once per week. It acts on melanocortin receptors. Common side effects include nausea (reported in roughly 40% of trial participants), flushing, and transient blood pressure increases.

Coverage under Amerigroup is similarly plan- and state-dependent. Because it is a specialty injectable, it often falls under the medical benefit rather than the pharmacy benefit, which changes the prior authorization pathway.

Pelvic Floor Physical Therapy

Amerigroup Medicaid plans typically cover physical therapy, and many pelvic floor therapists bill under standard PT procedure codes. If you have genitopelvic pain disorder, dyspareunia from pelvic floor dysfunction, or vaginismus, a referral to a pelvic floor physical therapist may be one of the most covered, evidence-supported options available to you. ACOG Practice Bulletin 236 on female sexual dysfunction names pelvic floor physical therapy as a recommended first-line intervention.

Hormone Therapy for Sexual Symptoms in Perimenopause and Menopause

If your sexual symptoms, low desire, vaginal dryness, painful penetration, difficulty with orgasm, are driven by the hormonal changes of perimenopause or menopause, hormone therapy is a different conversation from Viagra or HSDD drugs. Low-dose vaginal estrogen and systemic hormone therapy are often covered under Amerigroup plans when prescribed for documented menopausal symptoms. The Menopause Society (formerly NAMS) 2022 Position Statement supports low-dose vaginal estrogen as first-line therapy for genitourinary syndrome of menopause (GSM), which commonly causes painful sex and reduced desire in this life stage.

Ospemifene (Osphena), an oral selective estrogen receptor modulator approved for dyspareunia from GSM, is another option your clinician might prescribe. Coverage depends on formulary placement, but it is at least a drug with an FDA-approved women's indication, making coverage appeals more viable.

Pregnancy, Lactation, and Contraception: A Required Safety Section

This section applies to every drug discussed above, and the information is not optional reading.

Flibanserin in Pregnancy and Lactation

Flibanserin is pregnancy category not formally assigned post-2015, but FDA labeling states it should not be used in pregnancy. Animal reproductive studies showed developmental toxicity at doses below the human therapeutic dose. There are no adequate human data in pregnant women. If you are trying to conceive or could become pregnant, you should use reliable contraception during flibanserin use and discontinue it before attempting pregnancy.

Lactation transfer of flibanserin has not been studied in humans. The FDA label states that breastfeeding is not recommended during flibanserin use because the drug is present in rat milk, and the potential for adverse effects in a nursing infant cannot be excluded.

Bremelanotide in Pregnancy and Lactation

Bremelanotide is contraindicated in pregnancy. FDA labeling for bremelanotide notes that animal studies showed fetal harm at exposures below the human therapeutic dose, including darkened fetal fur pigmentation due to the drug's melanocortin receptor mechanism. Women who may become pregnant should use effective contraception. Because bremelanotide is used on-demand rather than daily, a reliable long-acting contraceptive method (IUD, implant, or similar) is preferable to methods requiring perfect daily adherence.

Lactation data are absent. The drug should not be used while breastfeeding given the unknown risk.

Sildenafil in Pregnancy

Sildenafil is not approved for women's sexual dysfunction, but it has been studied in obstetric contexts, primarily for fetal growth restriction and pulmonary hypertension in pregnancy. A Dutch trial (STRIDER NL) testing sildenafil for severe early-onset fetal growth restriction was halted early due to increased neonatal pulmonary hypertension deaths in the sildenafil group. This is a serious safety signal. No woman should use sildenafil during pregnancy without close specialist supervision, and self-medicating off-label with sildenafil during pregnancy is dangerous.

Vaginal Estrogen and Ospemifene in Pregnancy

Vaginal estrogen is contraindicated in pregnancy. Ospemifene is contraindicated in pregnancy. If you are in perimenopause and also still cycling with any chance of conception, confirm your contraceptive status before starting either agent.

Who This Is Right For and Who Should Look Elsewhere

The following framework is designed to help you identify which sexual health benefit to pursue under your Amerigroup plan based on your life stage and symptom pattern. No tool replaces a clinical conversation, but this gives you a starting point.

Premenopausal Women with Low Desire and Personal Distress

You are the primary population studied for flibanserin and bremelanotide. HSDD is defined as low desire that causes meaningful personal distress, without a clear relationship or situational explanation. If that description fits, ask your Amerigroup plan specifically about flibanserin coverage under the pharmacy benefit and bremelanotide under the medical benefit. Document your symptoms in terms of frequency, duration (typically at least 6 months for a diagnosis), and distress level. Your clinician needs those details to justify prior authorization.

Women Trying to Conceive

Neither flibanserin nor bremelanotide should be used when you are trying to conceive. Sildenafil is not a safe self-treatment option either. If sexual pain is the barrier to conception, pelvic floor physical therapy and a referral to a reproductive endocrinologist or gynecologist for structural evaluation (rule out endometriosis, vaginismus, pelvic inflammatory disease) are the right next steps and are more likely to be covered.

Perimenopausal Women (Typically Ages 40-52)

Your sexual symptoms may be driven by fluctuating estrogen and progesterone, not a primary desire disorder. Vaginal dryness causing pain, reduced clitoral sensitivity from tissue changes, and mood-related low desire from sleep disruption and vasomotor symptoms all respond better to hormone management than to HSDD-specific drugs. ACOG Practice Bulletin 141 on management of menopausal symptoms provides clinical guidance your provider can reference when documenting medical necessity for hormone therapy coverage.

The HSDD drugs were not studied in women with concurrent untreated menopause symptoms. Getting the hormonal substrate right first often resolves the desire problem without additional medication.

Postmenopausal Women

Flibanserin is approved only for premenopausal women. Bremelanotide's label also specifies premenopausal women, though off-label use in postmenopausal women occurs. A 2017 study in Menopause journal looked at bremelanotide in naturally and surgically menopausal women and found improved desire scores, but this is not the approved population. Getting Amerigroup to cover off-label use in a postmenopausal woman faces a higher prior authorization bar.

Postmenopausal women with GSM-related sexual symptoms have clearer coverage pathways through vaginal estrogen, ospemifene, or the DHEA vaginal insert prasterone (Intrarosa), which is FDA-approved for dyspareunia due to GSM and has a stronger case for formulary coverage than HSDD-specific agents.

Women with PCOS

PCOS affects roughly 8-13% of women of reproductive age and is associated with androgen excess, insulin resistance, and often with sexual dysfunction related to body image, mood, and hormonal imbalance. Testosterone is not FDA-approved for women in the United States, but some clinicians prescribe it off-label for low desire in PCOS. Coverage is almost universally denied because there is no approved female indication. If testosterone is something you want to discuss, frame the conversation around your overall PCOS management, not sexual health specifically, when talking to your insurer.

How to Actually Get Coverage or Lower Your Costs

Getting a "no" from Amerigroup on a first pharmacy claim is not the end of the conversation.

Step 1: Request a Formulary Exception

If flibanserin or bremelanotide is not on your plan's formulary, your prescriber can submit a formulary exception request. This requires documentation that the drug is medically necessary and that alternatives are clinically inappropriate for you. Your clinician should reference the FDA approval and the ISSWSH (International Society for the Study of Women's Sexual Health) clinical practice guidelines, which support pharmacotherapy for HSDD when non-pharmacological options have not adequately addressed distress.

Step 2: File a Prior Authorization or Appeal

If a prior authorization is denied, you have the right to appeal. Federal law requires Amerigroup to provide you a written denial with the clinical criteria used. Your prescriber's letter should directly address those criteria. A second-level appeal reviewed by a physician not involved in the original denial is standard under Medicaid managed care contracts.

Step 3: Manufacturer Assistance Programs

Sprout Pharmaceuticals (flibanserin) and AMAG Pharmaceuticals (bremelanotide) offer patient assistance programs. These do not depend on Amerigroup coverage and may provide the medication free or at reduced cost if you meet income criteria.

Step 4: Community Health Centers

Federally Qualified Health Centers (FQHCs) operate on sliding-scale fees and employ clinicians who can prescribe, document, and manage formulary exceptions. If your current provider is not familiar with HSDD coding and prior authorization requirements, an FQHC women's health clinician may be a more effective advocate.

The Evidence Gap You Should Know About

Women have been systematically under-represented in sexual health research for decades. Erectile dysfunction research in men has decades of investment; female sexual dysfunction research is a much younger field with far less industry funding and regulatory history. A 2018 analysis in the Journal of Women's Health documented that women made up only 38% of participants in sexual medicine clinical trials published between 2000 and 2016.

What this means practically: the absence of strong evidence for a treatment in women often reflects the absence of research, not the absence of effect. When your clinician says "there's not much data on this in women," that is an honest statement about the research pipeline, not a reason to dismiss your symptoms. Push for a referral to a specialist if your primary care provider is not familiar with HSDD or female sexual dysfunction management.